Moderna teams up with Karolinska to flesh out its mRNA promise

Well-funded biotech Moderna Therapeutics has inked a long-term deal with Sweden's Karolinska Institutet to spotlight new applications for the company's messenger RNA technology. Under the agreement, Moderna will sponsor research grants to support Karolinska scientists with preclinical ideas for its mRNA platform, taking the best and brightest programs into the clinic on its own. Moderna's flagship technology has the potential to spur the production of human proteins or antibodies within patient cells, effectively creating an in vivo factory for targeted therapies. And the Karolinska deal, the company's first academic partnership, is an effort to expand its applications, CEO Stéphane Bancel said. Moderna, a 2013 Fierce 15 winner, has pulled in more than $300 million in venture and partnership cash since its 2012 foundation, teaming up with the likes of AstraZeneca ($AZN) and Alexion ($ALXN) along the way. More

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.